Scemblix 40 mg film-coated tablets, Scemblix 20 mg film-coated tablets, Iclusig 45 mg film-coated tablets clinical trials

Safety and efficacy of treatment combination with ponatinib and asciminib in chronic myeloid leukemia patients resistant to ponatinib and/or asciminib

This study is looking at a new combination of two existing medicines, Scemblix and Iclusig, for people with chronic myeloid leukemia (CML). It aims to see how safe and effective this combination is when current treatments aren't working as well as they should.